Vikrant Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
- Paid Up Capital ₹ 2.24 Cr
- Company Age 41 Year, 5 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.01 Cr
- Satisfied Charges ₹ 2.67 M
- Revenue Growth %
- Profit Growth -223.38%
- Ebitda -241.91%
- Net Worth -0.90%
- Total Assets -0.92%
About Vikrant Pharmaceuticals
Vikrant Pharmaceuticals Limited (VPL) is a Public Limited Indian Non-Government Company incorporated in India on 16 February 1984 and has a history of 41 years. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Vikrant Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 2.24 Cr.
The company currently has active open charges totaling ₹5.01 Cr. The company has closed loans amounting to ₹2.67 M, as per Ministry of Corporate Affairs (MCA) records.
Shruti Ladhani, Kamala Vastupal, and Vastupal Pratapchand serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U99999MH1984PLC032190
- Company No.
032190
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
16 Feb 1984
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Vikrant Pharmaceuticals Limited offer?
Vikrant Pharmaceuticals Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Anti Cancer Medicines, Pain Relief Drugs & Pharmaceuticals, Osteoporosis Medications, Arthritic Drugs, Steroid, Brain & Nervous System Drugs.
Who are the key members and board of directors at Vikrant Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vastupal Pratapchand ![]() | Managing Director | 17-Feb-1984 | Current |
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shruti Ladhani ![]() | Director | 27-Dec-2016 | Current |
Kamala Vastupal ![]() | Whole-Time Director | 15-Mar-1984 | Current |
Financial Performance of Vikrant Pharmaceuticals.
Vikrant Pharmaceuticals Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 223.38% decrease in profit. The company's net worth dipped by a decrease of 0.9%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Vikrant Pharmaceuticals?
In 2020, Vikrant Pharmaceuticals had a promoter holding of 16.92% and a public holding of 83.09%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹5.01 Cr
₹0.27 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 5.00 Cr
- Citibank Na : 0.01 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Nov 2014 | Bank Of India | ₹5.00 Cr | Open |
20 Feb 1988 | Citibank Na | ₹0.06 M | Open |
05 Jun 2010 | Syndicate Bank | ₹0.50 M | Satisfied |
15 Sep 1987 | New Bank Of India | ₹0.20 M | Satisfied |
21 Aug 1985 | New Bank Of India | ₹0.40 M | Satisfied |
How Many Employees Work at Vikrant Pharmaceuticals?
Unlock and access historical data on people associated with Vikrant Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Vikrant Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vikrant Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.